Monthly Meeting
Local Seminars
The Nucleus
Contact Us
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Medicinal Chemistry Group
Our Mission
The mission of the medicinal chemistry group is to advance knowledge and understanding of drug discovery research by organizing world class quality symposia.
Our meetings provide our attendees with access to top quality science presenters and offer unique networking connectivity with thought leaders in the scientific community.
Our members work at the forefront of the life science sector and are constantly striving to bring new medicines and therapies forward to the clinic to meet unmet need.

Volunteer Opportunities
The Medicinal chemistry group will be interested in volunteers to assist with annual symposium specifically for contacting potential vendors and fund-raising efforts. Please contact the med chem chair, Raj Rajur at rrajur@creagenbio.com, if interested.

Who are we?
     
   
  Dr. Raj (SB) Rajur, Chair
  rrajur@creagenbio.com
   
 
   
  Mark Ashwell
  Nimbus Therapeutics
mashwellmail@gmail.com
   
   
  Daniel Elbaum
  Retrophin
ddelbaum@msn.com
   
 
   
  Andrew Scholte
  Sanofi
Andrew.Scholte@genzyme.com
   
   
  Jeremy Green
  Vertex
jeremy_green@vrtx.com
   
 
   
  Blaise Lippa
  Morphic Therapeutic
Blaise.Lippa@morphictx.com
   
   
  Adrian Hobson
  Abbvie
   
 
   
  Alan Rigby
  Warp Drive Bio
   

SYMPOSIUM
“Recent Advances in Cancer Therapy”

Organized by BMS Discovery Chemistry, Cambridge and the Medicinal Chemistry Section
of the Northeastern Section, American Chemical Society

Sponsored By
Wednesday – February 6th, 2019
Bristol-Myers Squibb Research and Development
100 Binney Street, Cambridge, MA 02142
Multipurpose Room
 
Download Flyer here ...

 
3:00 pm Refreshments
3:15 pm Welcome - Raj Rajur, Medicinal Chemistry Program Chair, CreaGen Inc., Woburn, MA
3:20 pm
Introductory Remarks
Gregory Vite, Ph.D.
Head, Oncology Discovery Chemistry and New Modalities
Bristol-Myers Squibb
3:00 - 4:15 pm
Jared Cumming, Ph.D.
Executive Director, Discovery Chemistry
Merck, Boston, MA
Title: Novel STING agonists: Activating the Innate Immune System to Fight Cancer
4:15 - 5:00 pm
Vasanthi Viswanathan, Ph.D.
Broad Institute of MIT and Harvard, Cambridge, MA
Title: Chemical Biology-Based Approach to Understanding and Overcoming Cancer Therapy Resistance
5:00 - 5:45 pm
Scott Biller, Ph.D.
Chief Scientific Officer
Agios, Cambridge, MA
Title: IDH Inhibitors: from Bench to Bedside and Back
6:00 - 6:30 pm Social Hour
6:30 - 7:30 pm Dinner
7:30 - 8:30 pm
Keynote Presentation
Prof. Nathanael Gray, Ph.D.
Harvard Medical School and Dana Farber Cancer Institute, Boston, MA
Title: Targeted Protein Degradation as a New Drug Development Strategy
 

Title: Targeted Protein Degradation as a New Drug Development Strategy

Professor Nathanael Gray

Harvard Medical School and Dana Farber Cancer Institute, Boston, MA

 

 

     
Professor Nathanael Gray
Harvard Medical School and Dana Farber Cancer Institute, Boston, MA

YOU MUST REGISTER IN ADVANCE TO ATTEND THE MEETING:  THERE IS NO REGISTRATION FEE TO ATTEND THE MEETING; DINNER RESERVATIONS ARE REQUIRED. PUBLIC IS INVITED
Symposium Organizing Committee:
Kap-Sun Yeung, Matthew Hill, Swanee Jacutin-Porte, Andrew Scholte, Raj (SB) Rajur

Bristol-Myers Squibb Cambridge Research Site
The Bristol-Myers Squibb Cambridge research site is located at 100 Binney Street, Cambridge, MA 02142, between Second Street and Third Street.
It is within walking distance of the MBTA Kendall station on the Red Line (about 0.3 miles) or the Lechmere station on the Green Line (about 0.5 miles).
Parking Garage: There are several parking garages within walking distance from BMS. The closest one is behind the BMS building on Linskey Way, between East Kendall Street and Second Street.

Medicinal Chemistry Group Hosts Symposium on The Future of Anti-Infectives

By Mindy Levine
On Thursday September 13, 2018, approximately 70 medicinal chemists (and other chemists interested in medicinal chemistry) gathered together at Takeda Pharmaceuticals for a half-day symposium on the topic of “The Future of Anti-infectives.” This symposium was sponsored by Takeda Pharmaceuticals and was organized by the Medicinal Chemistry Group of the Northeastern Section of the American Chemical Society.
The medicinal chemistry group, organized by Dr. Raj Rajur of Creagen Bio and Dr. Andrew Scholte of Sanofi,
hosts half-day symposia twice a year, in September and in December, at a variety of pharmaceutical companies throughout the greater Boston area.
The full speaker lineup for the September event is shown below:
Afternoon speakers:
  • Kim Lewis, Northeastern University, Title: Reviving Antibiotic Discovery from Natural Products
  • Thomas Durand Reville, Entasis, Title: The rational design and discovery of ETX2514, a novel broad-spectrum β-lactamase inhibitor for the treatment of Gram-negative infections
  • Roger Clark, Macrolide, Title: Novel Macrolides for Gram-Negative Infections
After the afternoon speakers, there was a break for social hour and dinner, followed by the plenary evening lecture presented by Jacques Dumas of Tetraphase. The title of the talk was “TP-6076: taking chemistry to the next level to beat superbug.”
Overall, the attendees had uniformly positive things to say about the symposium, with attendees highlighting
the timeliness of the topic, the relevance to their careers, and the important networking opportunities provided through attending these symposia.
Stay tuned for the next medicinal chemistry symposium, coming in December 2018!